Critical Outcome Technologies Inc. (COTI)

Critical Outcome Technologies Inc. (COTI)

October 15, 2009 10:58 ET

COTI-2 Is an Effective Single Agent With Low Toxicity in Multiple Xenograft Models of Human Cancers

LONDON, ONTARIO--(Marketwire - Oct. 15, 2009) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) released a summary of animal data today clearly demonstrating that COTI-2 is an effective single agent with low toxicity in six different xenograft models of human cancers.

Generally, attempts to extrapolate from an individual animal model of human cancer to successful human drug trials have been unsuccessful. However, Voskoglou-Nomikos et al (Clinical Cancer Research, 2003) have provided evidence that where an early stage compound produces significant tumor growth inhibition in multiple xenograft models of human cancers there can be a significant correlation with that compound's Phase 2 clinical success. For that reason COTI-2, a novel AKT inhibitor, was studied in multiple xenograft models of a range of human cancers.

COTI-2, when administered at doses from 3 mg/kg to 125 mg/kg and with dosing schedules ranging from 3 times per week to 5 times per week, significantly inhibited tumor growth in multiple human cancers. These results are summarized in Table 1 below. COTI-2 is an effective single agent since doses as low as 3 mg/kg and a low dose short course of just 5 treatments given over 10 days produced significant tumor growth inhibition in different tumors. In addition, higher doses given up to 5 times per week and for longer periods produced even greater tumor growth inhibitor effects (average TGI = 63.3% for treatments = 19 days). COTI-2 also demonstrated low toxicity since doses up to 125 mg/kg administered for up to 36 days were well tolerated by the animals.

Table 1: A summary of the single agent activity of COTI-2 in six xenograft models of human cancer 

Cell line         CancerType    Model     Dose(mg/kg)  RouteTx Days  Schedule  TGI (%)  p Value
 SHP77  Small Cell    Metastatic    3 – 4 IP 38  3 times per 96.2  < 0.01
   Lung          week    
 N417  SCLC    Solid    Up to 30 IP 29  5 times per 56.8  < 0.05
 HT29  Colon    Solid    Up to 10 IP 48  5 times per 54.9  < 0.05
 U87  Brain    Solid    Up to 8 IP 10  3 times per 30.0  < 0.05
 U937  Leukemia    Solid    Up to 20 IP 19  5 times per 43.8  < 0.13
 A2780  Ovarian    Solid    Up to 125 PO 36  Dose range 64.7  0.05
 IP = Intraperitoneal    PO = Oral        TGI% = Tumor Growth Inhibition Percent              Tx = Treatment

"We are very pleased with the significant single agent efficacy and low toxicity of COTI-2 in multiple animal models of human cancers. While traditional cancer chemotherapy is frequently limited by significant toxic side effects, it is drug candidates like COTI-2 that represent a new generation of less toxic drugs with good anti- tumor activity," said COTI President and CSO, Dr. Wayne Danter. "This data clearly supports the continued development of COTI-2 into human clinical trials. We remain focused on solidifying a licensing agreement with an organization that can assist in advancing COTI-2 forward," said COTI CEO Mr. Michael Cloutier.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. Currently, six targeted libraries of lead compounds are under active development; small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, acute myelogenous leukemia, colorectal cancer and Alzheimer's disease.

For further information, please visit the website at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Critical Outcome Technologies Inc. (COTI)
    Michael Barr
    Director of Business Development and Marketing